Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BioRestorative Therapies, Inc.
Report date October 06, 2025 · Filed October 20, 2025
Section 16 reporting ended · disclosed 2025-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Comon StockSEC Table I · non-derivative | Direct | 171,384 |
Reported balance
After 2025-10-06 transaction · row 1
1 source rowRow 1 · 2025-10-06 · Grant · Acquired 11,719 · Balance 171,384 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2030-10-08 | Direct | 11,719 |
Reported balance
After 2025-10-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-10-06 · Grant · Acquired 11,719 · Balance 11,719 |
| Common StockSEC Table I · non-derivative | IndirectIRA | 12,136 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,136 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2026-06-10 | Direct | 15 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 15 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2027-07-12 | Direct | 20 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 20 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2028-10-29 | Direct | 25 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 25 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-03-18 | Direct | 293,479 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 293,479 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 42,059 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 42,059 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 106,762 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 106,762 F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 394,737 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 394,737 F3: The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 768,979 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 768,979 F4: The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F3: The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
F4: The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2017 Filed Feb 15, 2017 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 4,000 | Not disclosed Strike: $10.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007721 · doc1.xml · derivative · entry 1 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2021-04-04 F10 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 2,000 shares on each of April 5, 2011 and April 5, 2012. Read SEC document |
| February 09, 2017 Filed Mar 1, 2017 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,800 | $4.38 | $7,884.00 |
DisclosureSEC source: 0001140361-17-009952 · doc1.xml · nonDerivative · entry 6 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,075 Read SEC document |
| February 02, 2017 Filed Mar 1, 2017 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,250 | $4.25 | $9,562.50 |
DisclosureSEC source: 0001140361-17-009952 · doc1.xml · nonDerivative · entry 5 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,275 Read SEC document |
| June 11, 2014 Filed Mar 1, 2017 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 20 | $7.60 | $152.00 |
DisclosureSEC source: 0001140361-17-009952 · doc1.xml · nonDerivative · entry 3 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 170 Read SEC document |
| June 10, 2014 Filed Mar 1, 2017 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 25 | $7.60 | $190.00 |
DisclosureSEC source: 0001140361-17-009952 · doc1.xml · nonDerivative · entry 4 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25 Read SEC document |
| December 26, 2013 Filed Mar 1, 2017 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 100 | $10.40 | $1,040.00 |
DisclosureSEC source: 0001140361-17-009952 · doc1.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 150 Read SEC document |
| July 17, 2013 Filed Mar 1, 2017 21:03 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 50 | $10.40 | $520.00 |
DisclosureSEC source: 0001140361-17-009952 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 50 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.